Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Palonosetron (ausschl. Dafo. WKA), ATC A04AA05 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Monate)

DAK-GesundheitHamburg, GermanyEUR 1 / ~EUR 11082 days leftopen

Registrieren zum Speichern Documents (1)

Opportunity Score

Confidence: 35%

Complexity: low

1082 days

Deadline

supplies

Contract

Deep Portfolio Analysis

Company fit score
Missing certificates
Eligibility blockers
Bid / No-Bid recommendation

Create account for AI analysis

AI Analysis Summary

Moderate opportunity

This is a non-exclusive, open-house framework rebate agreement (Rabattvereinbarung nach §130a Abs. 8 SGB V) for the active substance Palonosetron (WKA only, ATC A04AA05). The tender allows any pharmaceutical company to join at any time during the contract period (01.08.2026 – 31.07.2028, with a 12-month extension option). It is not a traditional procurement under EU directives but is published for transparency. The estimated value is symbolic (€1). Submission is via email, and the documentation is available on the DTVP portal.

Strengths

Documents available

Open procedure

Low complexity

Key Requirements

Submission of the official offer letter (Angebotsschreiben)
Acceptance of DAK-Gesundheit's contractual terms, including agreed rebates
Completion of Annexes 1 and 2 to the contract (Annex 2 must be in Excel format)

Buyer

Name

DAK-Gesundheit

Location

Hamburg, DEU

[email protected]

Website

www.dak.de

Identifier

DE48698890

Lots (1)

#LOT-0001Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Palonosetron (ausschl. Dafo. WKA), ATC A04AA05 f. d. Z. 01.08.2026 - 31.07.2028 (zzgl. V.-Option 1x12 Monate)

Non-exclusive rebate agreement for Palonosetron (WKA only) under §130a SGB V. Contract duration 24 months (starting 01.08.2026, ending 31.07.2028) with a possible 12-month extension. The agreement automatically terminates if an exclusive contract for the same active substance is concluded. The process is an open-house model; any pharmaceutical company can join by submitting required documents.

EUR 133600000DEU